Ionis Pharmaceuticals said the FDA granted a label expansion for its antisense therapy Tryngolza to reduce triglycerides and treat patients with severe hypertriglyceridemia and associated pancreatitis risk, expanding the drug’s commercial footprint. The update follows the agency’s continued focus on high-unmet-need lipid disorders where cardiovascular and pancreatitis risks overlap, with antisense approaches offering dose-adjusted, triglyceride-lowering mechanisms that differ from standard small-molecule therapies. For Ionis, the broader indication set increases potential addressable patient pools, supporting more durable revenue expectations as the company scales production and payer access efforts for a therapy positioned at the intersection of endocrinology and acute care risk. The label change also reinforces regulatory momentum for RNA-targeted modalities beyond oncology, where antisense has already secured multiple launches and expansions.